Ibex Medical Analytics Secures $38M for AI Cancer Diagnostics

Ibex Medical Analytics Secures $38 Million in Series B Funding

Ibex Medical Analytics, an Israeli company specializing in AI-powered imaging for cancer detection, has successfully closed a $38 million Series B funding round. The investment was spearheaded by Octopus Ventures and 83North.

Additional participation in this round came from existing investors including aMoon, Planven Entrepreneur Ventures, and Dell Technologies Capital, the venture capital division of Dell Technologies.

Total Funding and Company History

Since its inception in 2016, Ibex Medical Analytics has now accumulated a total of $52 million in funding. The company intends to utilize these newly acquired funds to expand its market reach.

Specifically, Ibex plans to increase sales and implementation of its technology within diagnostic laboratories across both North America and Europe.

The Galen Platform and its Functionality

Ibex’s core technology, the Galen platform, originated within the Kamet Ventures incubator. This platform is designed to emulate the analytical capabilities of a pathologist.

It aims to enhance the accuracy and speed of cancer diagnoses, while also facilitating the discovery of novel insights from biopsy samples.

Addressing Challenges in Pathology

The demand for pathology services is increasing due to rising cancer rates and the growing complexity of medical procedures. This has resulted in a significant workload for pathologists.

Furthermore, a global shortage of qualified pathologists is contributing to delays in the diagnostic process. Ibex asserts that its solution can improve pathologist productivity by up to 40%.

How the Technology Assists Pathologists

According to Joseph Mossel, CEO and co-founder of Ibex, in an interview with TechCrunch, the platform functions as a virtual assistant for pathologists.

Galen pre-processes cases, identifies areas of interest, and ultimately enables pathologists to work more efficiently.

Key Partnerships and Network Reach

Ibex has already established significant partnerships, including securing a contract with the largest pathology network in France.

The company also collaborates with LD Path, a network of five pathology labs serving 24 NHS trusts throughout the United Kingdom.

Kamet Ventures' Role in Ibex's Development

Michael Niddam, representing Kamet Ventures, highlighted Ibex as a prime example of Kamet’s collaborative approach with early-stage founders.

Founders Joseph Mossel and Dr. Chaim Linhart initially joined Kamet as Entrepreneurs in Residence before conceptualizing and developing the Ibex platform.